SG11201802073YA - Pharmaceutical composition containing anionic drug, and preparation method therefor - Google Patents
Pharmaceutical composition containing anionic drug, and preparation method thereforInfo
- Publication number
- SG11201802073YA SG11201802073YA SG11201802073YA SG11201802073YA SG11201802073YA SG 11201802073Y A SG11201802073Y A SG 11201802073YA SG 11201802073Y A SG11201802073Y A SG 11201802073YA SG 11201802073Y A SG11201802073Y A SG 11201802073YA SG 11201802073Y A SG11201802073Y A SG 11201802073YA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- pharmaceutical composition
- composition containing
- method therefor
- containing anionic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150130587 | 2015-09-15 | ||
KR1020160117053A KR101828877B1 (en) | 2015-09-15 | 2016-09-12 | Pharmaceutical Composition Containing Anionic Drug and Preparation Method of the Same |
PCT/KR2016/010269 WO2017048018A1 (en) | 2015-09-15 | 2016-09-12 | Pharmaceutical composition containing anionic drug, and preparation method therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201802073YA true SG11201802073YA (en) | 2018-04-27 |
Family
ID=58496160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201802073YA SG11201802073YA (en) | 2015-09-15 | 2016-09-12 | Pharmaceutical composition containing anionic drug, and preparation method therefor |
Country Status (16)
Country | Link |
---|---|
US (2) | US11253598B2 (en) |
EP (1) | EP3357491B1 (en) |
JP (1) | JP6638072B2 (en) |
KR (2) | KR101828877B1 (en) |
CN (1) | CN108024960B (en) |
AU (1) | AU2016324450B2 (en) |
CA (1) | CA2998092C (en) |
DK (1) | DK3357491T3 (en) |
ES (1) | ES2883290T3 (en) |
HK (1) | HK1251464A1 (en) |
IL (1) | IL257937B (en) |
MX (1) | MX2018003096A (en) |
PT (1) | PT3357491T (en) |
RU (1) | RU2721558C2 (en) |
SG (1) | SG11201802073YA (en) |
ZA (1) | ZA201802303B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3008788C (en) * | 2015-12-18 | 2021-05-25 | Samyang Biopharmaceuticals Corporation | Method for preparing polymeric micelles containing an anionic drug |
KR102175069B1 (en) * | 2017-11-10 | 2020-11-05 | 주식회사 삼양바이오팜 | Composition and process for freeze-drying of lipid nanoparticles for delivering an anionic drug |
KR102259513B1 (en) * | 2017-11-16 | 2021-06-02 | 주식회사 삼양홀딩스 | Composition and process for freeze-drying of a pharmaceutical composition containing an anionic drug |
KR20190127277A (en) * | 2018-05-04 | 2019-11-13 | 주식회사 삼양바이오팜 | Polymeric nanoparticle composition for delivering mRNA and preparation method thereof |
CN109136271B (en) * | 2018-09-20 | 2021-07-20 | 西北工业大学 | Application of cationic polyvinylamine linear polymer as transgenic vector |
CA3157437A1 (en) | 2019-11-07 | 2021-05-14 | So Jin Lee | Polymer nanoparticle composition for inducing immunity and preparation method therefor |
CA3159021A1 (en) * | 2019-11-22 | 2021-05-27 | So Jin Lee | Kit for preparing nanoparticle composition for drug delivery |
US20230039124A1 (en) * | 2019-12-20 | 2023-02-09 | Samyang Holdings Corporation | Kit for preparing nanoparticle composition for drug delivery, comprising polylactic acid salt |
EP4331576A1 (en) * | 2021-04-30 | 2024-03-06 | Samyang Holdings Corporation | Composition for drug delivery comprising nanoparticles not containing amphiphilic polymer |
GB202108444D0 (en) * | 2021-06-14 | 2021-07-28 | Imperial College Innovations Ltd | Sub-micron particle |
CN114569577B (en) * | 2022-03-07 | 2023-04-11 | 晟迪生物医药(苏州)有限公司 | Polymer coated nanoparticle and preparation method thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0180334B1 (en) | 1995-09-21 | 1999-03-20 | 김윤 | Drug messenger using el-2l-2 micelle and method for sealing drug to it |
US6458382B1 (en) | 1999-11-12 | 2002-10-01 | Mirus Corporation | Nucleic acid transfer complexes |
ES2336887T5 (en) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediators of RNA interference specific to RNA sequences |
EP1463518A2 (en) | 2001-12-28 | 2004-10-06 | Supratek Pharma, Inc. | Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression |
AU2003288902A1 (en) | 2002-09-06 | 2004-04-08 | Genteric, Inc. | Microcapsules and methods of use |
KR100829799B1 (en) * | 2004-05-06 | 2008-05-16 | 주식회사 삼양사 | Delivery composition for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylactic acid |
KR100949791B1 (en) | 2007-12-18 | 2010-03-30 | 이동기 | Novel siRNA Structure for Minimizing Off-target Effects and Relaxing Saturation of RNAi Machinery and the Use Thereof |
US20090312402A1 (en) * | 2008-05-20 | 2009-12-17 | Contag Christopher H | Encapsulated nanoparticles for drug delivery |
KR20110051214A (en) * | 2008-07-30 | 2011-05-17 | 닛토덴코 가부시키가이샤 | Drug carriers |
NZ594245A (en) | 2008-12-26 | 2013-02-22 | Samyang Biopharmaceuticals | Pharmaceutical composition containing an anionic drug, a cationic lipid and an amphiphilic block copolymer |
AU2009331027B2 (en) * | 2008-12-26 | 2012-12-13 | Samyang Holdings Corporation | Preparation method of polymeric micellar nanoparticles composition containing a poorly water-soluble drug |
KR101296326B1 (en) * | 2009-12-30 | 2013-08-14 | 주식회사 삼양바이오팜 | Composition for Delivery of Anionic Drugs Containing Poly-lactic Acid and Preparation Method thereof |
US9314529B2 (en) * | 2010-07-09 | 2016-04-19 | The University Of Tokyo | Nucleic acid delivery composition and carrier composition, pharmaceutical composition using the same, and method for nucleic acid delivery |
EP3695850A1 (en) * | 2010-12-30 | 2020-08-19 | Samyang Biopharmaceuticals Corporation | Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof |
ES2836279T3 (en) * | 2012-04-04 | 2021-06-24 | Samyang Biopharmaceuticals | Method of preparing a composition for administering an anionic drug |
KR102109188B1 (en) | 2013-04-01 | 2020-05-11 | 삼성전자주식회사 | Temperature sensitive liposome comprising cationic lipid and use thereof |
JP2016526011A (en) | 2013-04-09 | 2016-09-01 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | Combination therapy nanoparticles |
-
2016
- 2016-09-12 EP EP16846839.5A patent/EP3357491B1/en active Active
- 2016-09-12 CN CN201680053810.0A patent/CN108024960B/en active Active
- 2016-09-12 SG SG11201802073YA patent/SG11201802073YA/en unknown
- 2016-09-12 RU RU2018113459A patent/RU2721558C2/en active
- 2016-09-12 AU AU2016324450A patent/AU2016324450B2/en active Active
- 2016-09-12 MX MX2018003096A patent/MX2018003096A/en unknown
- 2016-09-12 DK DK16846839.5T patent/DK3357491T3/en active
- 2016-09-12 CA CA2998092A patent/CA2998092C/en active Active
- 2016-09-12 PT PT168468395T patent/PT3357491T/en unknown
- 2016-09-12 US US15/759,943 patent/US11253598B2/en active Active
- 2016-09-12 KR KR1020160117053A patent/KR101828877B1/en active IP Right Grant
- 2016-09-12 JP JP2018533597A patent/JP6638072B2/en active Active
- 2016-09-12 ES ES16846839T patent/ES2883290T3/en active Active
-
2018
- 2018-01-16 KR KR1020180005600A patent/KR101948839B1/en active IP Right Grant
- 2018-03-07 IL IL257937A patent/IL257937B/en active IP Right Grant
- 2018-04-09 ZA ZA2018/02303A patent/ZA201802303B/en unknown
- 2018-08-24 HK HK18110936.6A patent/HK1251464A1/en unknown
-
2022
- 2022-01-10 US US17/572,195 patent/US20220125929A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2018113459A3 (en) | 2019-10-18 |
JP2018527413A (en) | 2018-09-20 |
ES2883290T3 (en) | 2021-12-07 |
CA2998092A1 (en) | 2017-03-23 |
AU2016324450A1 (en) | 2018-04-12 |
ZA201802303B (en) | 2019-01-30 |
US20220125929A1 (en) | 2022-04-28 |
PT3357491T (en) | 2021-08-02 |
CN108024960A (en) | 2018-05-11 |
DK3357491T3 (en) | 2021-08-02 |
KR20180008854A (en) | 2018-01-24 |
EP3357491A1 (en) | 2018-08-08 |
RU2721558C2 (en) | 2020-05-20 |
IL257937B (en) | 2020-10-29 |
EP3357491B1 (en) | 2021-06-02 |
CN108024960B (en) | 2020-12-29 |
US20180250409A1 (en) | 2018-09-06 |
US11253598B2 (en) | 2022-02-22 |
RU2018113459A (en) | 2019-10-18 |
EP3357491A4 (en) | 2019-05-08 |
MX2018003096A (en) | 2018-05-11 |
CA2998092C (en) | 2020-08-04 |
IL257937A (en) | 2018-05-31 |
AU2016324450B2 (en) | 2019-04-18 |
KR20170032858A (en) | 2017-03-23 |
HK1251464A1 (en) | 2019-02-01 |
KR101948839B1 (en) | 2019-02-15 |
JP6638072B2 (en) | 2020-01-29 |
KR101828877B1 (en) | 2018-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251464A1 (en) | Pharmaceutical composition containing anionic drug, and preparation method therefor | |
PL3453707T3 (en) | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | |
HK1255566A1 (en) | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | |
EP3130354A4 (en) | Posaconazole pharmaceutical composition and preparation method, application and pharmaceutical preparation thereof | |
EP3351242A4 (en) | Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same | |
ZA201805600B (en) | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | |
IL252397A0 (en) | Pharmaceutical composition, preparation and uses thereof | |
HK1255062A1 (en) | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | |
IL290114A (en) | Pharmaceutical composition, preparation and uses thereof | |
EP3181553A4 (en) | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | |
EP3388433A4 (en) | Phthalazine derivatives, and preparation method, pharmaceutical composition and use thereof | |
IL258977B (en) | Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them | |
PL3391893T3 (en) | Pharmaceutical composition for treating leukemia and preparation method thereof | |
PL3229843T3 (en) | Pharmaceutical composition, preparation and uses thereof | |
SG11201610636VA (en) | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor | |
SG11201609948YA (en) | Lobaplatin crystal, preparation method and pharmaceutical application | |
EP3284743A4 (en) | Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof | |
HK1214767A1 (en) | Tablet-formed pharmaceutical composition and preparation method thereof | |
SI3250188T1 (en) | Pharmaceutical composition comprising aprepitant and method for the preparation thereof | |
IL262929A (en) | Composition, and application and pharmaceutical preparation thereof | |
GB201621559D0 (en) | A method for the preparation of a delivery drug delivery system and a composition therefor | |
EP3395371A4 (en) | Drug inclusion compound, preparation thereof, and preparation method therefor | |
IL266938A (en) | Pharmaceutical preparation and method for its manufacture | |
EP3251672A4 (en) | Pharmaceutical composition and preparation method therefor |